Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24)
Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup
(n=51)